Her primary scientific interests are in Cancer research, Receptor tyrosine kinase, Tyrosine kinase, Molecular biology and Hepatocyte growth factor. The Cancer research study combines topics in areas such as Cancer, Targeted therapy, Metastasis and Tumor progression. The study incorporates disciplines such as Cell surface receptor, Proto-oncogene tyrosine-protein kinase Src and Platelet-derived growth factor receptor in addition to Receptor tyrosine kinase.
Silvia Giordano works mostly in the field of Tyrosine kinase, limiting it down to concerns involving Drug resistance and, occasionally, Lung cancer, KRAS, Cetuximab, Panitumumab and Growth factor receptor. Her Hepatocyte growth factor research integrates issues from Cell culture, Epithelial polarity and Northern blot. Her Cell biology study which covers Receptor that intersects with Downregulation and upregulation.
Silvia Giordano mainly investigates Cancer research, Receptor tyrosine kinase, Tyrosine kinase, Cell biology and Cancer. Her studies in Cancer research integrate themes in fields like Hepatocyte growth factor, Cancer cell, Carcinogenesis, Oncogene and Targeted therapy. Her Receptor tyrosine kinase research is multidisciplinary, incorporating perspectives in Protein tyrosine phosphatase, Proto-oncogene tyrosine-protein kinase Src, ROR1, Platelet-derived growth factor receptor and Molecular biology.
In Tyrosine kinase, Silvia Giordano works on issues like Phosphorylation, which are connected to Tyrosine. Her Cell biology study integrates concerns from other disciplines, such as Semaphorin, Receptor and C-Met. Her work deals with themes such as Pathology, Oncology and Pharmacology, which intersect with Cancer.
Her primary areas of investigation include Cancer research, Cancer, Internal medicine, Oncology and Cancer cell. Her Cancer research study combines topics from a wide range of disciplines, such as Tyrosine kinase, Targeted therapy, Downregulation and upregulation and Transplantation. Her research investigates the connection with Tyrosine kinase and areas like Epidermal growth factor receptor which intersect with concerns in AXL receptor tyrosine kinase, Hippo signaling pathway, Cell biology and Epithelial–mesenchymal transition.
Her biological study spans a wide range of topics, including EGFR inhibitors and Signal transduction, Receptor tyrosine kinase. Her Cancer study incorporates themes from Cell culture and Clinical trial, Pathology. Her Cancer cell research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Selma Pennacchietti;Paolo Michieli;Maria Galluzzo;Massimiliano Mazzone.
Cancer Cell (2003)
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
Carola Ponzetto;Alberto Bardelli;Alberto Bardelli;Zhu Zhen;Flavio Maina.
Drug development of MET inhibitors : targeting oncogene addiction and expedience
Paolo M. Comoglio;Silvia Giordano;Livio Trusolino.
Nature Reviews Drug Discovery (2008)
Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer
M F Di Renzo;M Olivero;A Giacomini;H Porte.
Clinical Cancer Research (1995)
Expression of the Met/HGF receptor in normal and neoplastic human tissues.
M. F. Di Renzo;R. P. Narsimhan;M. Olivero;S. Bretti.
Tyrosine kinase receptor indistinguishable from the c-met protein.
S. Giordano;C. Ponzetto;M. F. Di Renzo;C. S. Cooper.
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli;Simona Corso;Andrea Bertotti;Sebastijan Hobor.
Cancer Discovery (2013)
The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met
Annalisa Petrelli;Giorgio F. Gilestro;Stefania Lanzardo;Paolo M. Comoglio.
The Semaphorin 4D receptor controls invasive growth by coupling with Met
Silvia Giordano;Simona Corso;Paolo Conrotto;Stefania Artigiani.
Nature Cell Biology (2002)
From single- to multi- target drugs in cancer therapy: when aspecificity becomes an advantage
Annalisa Petrelli;Silvia Giordano.
Current Medicinal Chemistry (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: